Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus Axitinib in Advanced HCC
NCT03289533Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2017
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in hepatocellular carcinoma (HCC), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events up to 21 months, Abnormal Laboratory Parameter Values (Hematology) up to 21 months and 1 more. Started Sep 2017; status: completed.
02
Drugs
avelumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03289533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289533.